256 related articles for article (PubMed ID: 20682656)
21. Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid.
Elad G; Paz A; Haklai R; Marciano D; Cox A; Kloog Y
Biochim Biophys Acta; 1999 Dec; 1452(3):228-42. PubMed ID: 10590312
[TBL] [Abstract][Full Text] [Related]
22. Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice.
Xiao Z; Li L; Li Y; Zhou W; Cheng J; Liu F; Zheng P; Zhang Y; Che Y
Cell Death Dis; 2014 May; 5(5):e1241. PubMed ID: 24853419
[TBL] [Abstract][Full Text] [Related]
23. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Makovski V; Haklai R; Kloog Y
Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
[TBL] [Abstract][Full Text] [Related]
24. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling.
Song S; Ji B; Ramachandran V; Wang H; Hafley M; Logsdon C; Bresalier RS
PLoS One; 2012; 7(8):e42699. PubMed ID: 22900040
[TBL] [Abstract][Full Text] [Related]
25. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
Gana-Weisz M; Halaschek-Wiener J; Jansen B; Elad G; Haklai R; Kloog Y
Clin Cancer Res; 2002 Feb; 8(2):555-65. PubMed ID: 11839677
[TBL] [Abstract][Full Text] [Related]
26. Runt-Related Transcription Factor 2 (Runx2) Is Responsible for Galectin-3 Overexpression in Human Thyroid Carcinoma.
Kaptan E; Sancar Bas S; Sancakli A; Aktas HG; Bayrak BB; Yanardag R; Bolkent S
J Cell Biochem; 2017 Nov; 118(11):3911-3919. PubMed ID: 28390192
[TBL] [Abstract][Full Text] [Related]
27. 6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells.
Zhao Y; Fan D; Ru B; Cheng KW; Hu S; Zhang J; Li ET; Wang M
Eur J Cancer; 2016 Nov; 68():38-50. PubMed ID: 27710830
[TBL] [Abstract][Full Text] [Related]
28. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
Laheru D; Shah P; Rajeshkumar NV; McAllister F; Taylor G; Goldsweig H; Le DT; Donehower R; Jimeno A; Linden S; Zhao M; Song D; Rudek MA; Hidalgo M
Invest New Drugs; 2012 Dec; 30(6):2391-9. PubMed ID: 22547163
[TBL] [Abstract][Full Text] [Related]
29. Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.
Shih TC; Fan Y; Kiss S; Li X; Deng XN; Liu R; Chen XJ; Carney R; Chen A; Ghosh PM; Lam KS
Neuro Oncol; 2019 Nov; 21(11):1389-1400. PubMed ID: 31127849
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats.
da Silva Morais A; Saliez A; Leclercq I; Horsmans Y; Stärkel P
Clin Sci (Lond); 2008 Jan; 114(1):73-83. PubMed ID: 17678500
[TBL] [Abstract][Full Text] [Related]
31. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
32. Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras.
Shalom-Feuerstein R; Levy R; Makovski V; Raz A; Kloog Y
Biochim Biophys Acta; 2008 Jun; 1783(6):985-93. PubMed ID: 18413234
[TBL] [Abstract][Full Text] [Related]
33. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Rotblat B; Ehrlich M; Haklai R; Kloog Y
Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
[TBL] [Abstract][Full Text] [Related]
34. Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib.
Faigenbaum R; Haklai R; Ben-Baruch G; Kloog Y
Oncotarget; 2013 Feb; 4(2):316-28. PubMed ID: 23530112
[TBL] [Abstract][Full Text] [Related]
35. Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer.
De Rose F; Braeuer M; Braesch-Andersen S; Otto AM; Steiger K; Reder S; Mall S; Nekolla S; Schwaiger M; Weber WA; Bartolazzi A; D'Alessandria C
J Nucl Med; 2019 Jun; 60(6):770-776. PubMed ID: 30361380
[TBL] [Abstract][Full Text] [Related]
36. Epigallocatechin gallate inhibits growth and epithelial-to-mesenchymal transition in human thyroid carcinoma cell lines.
De Amicis F; Perri A; Vizza D; Russo A; Panno ML; Bonofiglio D; Giordano C; Mauro L; Aquila S; Tramontano D; Andò S
J Cell Physiol; 2013 Oct; 228(10):2054-62. PubMed ID: 23553645
[TBL] [Abstract][Full Text] [Related]
37. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
38. Salirasib in the treatment of pancreatic cancer.
Bustinza-Linares E; Kurzrock R; Tsimberidou AM
Future Oncol; 2010 Jun; 6(6):885-91. PubMed ID: 20528225
[TBL] [Abstract][Full Text] [Related]
39. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
40. Vitamin D and S-farnesylthiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation.
Neeman R; Abramovitch S; Sharvit E; Elad-Sfadia G; Haklai R; Kloog Y; Reif S
Dig Dis Sci; 2014 Oct; 59(10):2462-9. PubMed ID: 24942325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]